BI 894999 First in Human Dose Finding Study in Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

July 8, 2015

Primary Completion Date

November 23, 2021

Study Completion Date

November 23, 2021

Conditions
NeoplasmsNUT Carcinoma
Interventions
DRUG

BI 894999

film-coated tablets

Trial Locations (16)

1070

Brussels - HOSP Jules Bordet, Anderlecht

1200

Brussels - UNIV Saint-Luc, Brussels

3000

UZ Leuven, Leuven

9000

UNIV UZ Gent, Ghent

10021

Memorial Sloan-Kettering Cancer Center, New York

13385

HOP Timone, Marseille

28041

Hospital Universitario 12 de Octubre, Madrid

44000

HOP Hôtel-Dieu, Nantes

44195

Cleveland Clinic, Cleveland

72076

Universitätsklinikum Tübingen, Tübingen

75475

HOP Saint-Louis, Paris

77030

The University of Texas MD Anderson Cancer Center, Houston

94800

INS Gustave Roussy, Villejuif

02215

Dana-Farber Cancer Institute, Boston

06351

Samsung Medical Center, Seoul

08035

Hospital Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY